| Market Cap | 14.65M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -574.27k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 60.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 42.00% |
| Dividend | N/A | Price/Book | 0.20 | EPS next 5Y | - | 52W High Chg | -33.00% |
| Recommedations | - | Quick Ratio | 8.42 | Shares Outstanding | 3.14B | 52W Low Chg | 300.00% |
| Insider Own | - | ROA | - | Shares Float | - | Beta | -0.75 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00040 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 240,713 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 600,000 | Change | 33.33% |
Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early diagnosis, and quick recovery of various diseases. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, thus permitting the physician to visualize the interior aspects of the breast; and OVASCOPE, an ultra slim endoscope to directly visualize the ovarian surface in the search for cancer. The company also has operations in Europe. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is headquartered in Reno, Nevada.
